Supriya Lifescience Limited
NSE:SUPRIYA.NS
648.3 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,661.02 | 1,606.26 | 1,581.8 | 1,400.74 | 1,400.95 | 1,320.21 | 1,422.71 | 1,051.4 | 1,121.72 | 1,013.55 | 1,775.74 | 1,170 | 1,478.58 | 769.42 | 1,296.48 | 806.91 |
| Cost of Revenue
| 459.75 | 733.37 | 793.19 | 546.21 | 616.39 | 472.2 | 475.62 | 513.48 | 468.92 | 350.13 | 1,049.134 | 417.92 | 436.14 | 395.67 | 527.59 | 327.55 |
| Gross Profit
| 1,201.27 | 872.89 | 788.61 | 854.53 | 784.56 | 848.01 | 947.09 | 537.92 | 652.8 | 663.42 | 726.606 | 752.08 | 1,042.44 | 373.75 | 768.89 | 479.36 |
| Gross Profit Ratio
| 0.723 | 0.543 | 0.499 | 0.61 | 0.56 | 0.642 | 0.666 | 0.512 | 0.582 | 0.655 | 0.409 | 0.643 | 0.705 | 0.486 | 0.593 | 0.594 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 69.73 | 0 | 0 | 0 | 58.43 | 0 | 0 | 0 | 187.16 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 173.92 | 0 | 0 | 0 | 165.03 | 0 | 0 | 0 | 72.18 | 0 |
| SG&A
| 357.25 | 294.03 | 272.71 | 264 | 292.02 | 154.28 | 243.65 | 251.03 | 7.75 | 224.27 | 223.46 | 184.03 | 94.04 | 83.76 | 259.34 | 107.64 |
| Other Expenses
| 601.54 | 22.24 | 21.85 | 30.65 | 24.67 | 29.18 | 19.64 | 25.64 | 26.05 | 23.57 | -106.91 | 54.42 | 33.21 | 19.39 | -66.32 | 43.29 |
| Operating Expenses
| 601.54 | 294.03 | 272.71 | 479.24 | 506.85 | 442.64 | 426.71 | 426.98 | 167.11 | 379.81 | -52.53 | 394.31 | 129.25 | 243.99 | 138.81 | 268.98 |
| Operating Income
| 599.73 | 578.86 | 515.9 | 405.93 | 302.38 | 405.36 | 540 | 136.57 | 511.74 | 283.61 | 796.24 | 357.77 | 946.41 | 149.15 | 630.08 | 210.38 |
| Operating Income Ratio
| 0.361 | 0.36 | 0.326 | 0.29 | 0.216 | 0.307 | 0.38 | 0.13 | 0.456 | 0.28 | 0.448 | 0.306 | 0.64 | 0.194 | 0.486 | 0.261 |
| Total Other Income Expenses Net
| 20.91 | 18.88 | 15.85 | -4.94 | -4.6 | 21.01 | -7.11 | -10.14 | -237.55 | 17.75 | -41.44 | 42.93 | -168.87 | -9.74 | 27.18 | 35.15 |
| Income Before Tax
| 620.64 | 597.74 | 531.75 | 400.99 | 297.78 | 426.38 | 532.89 | 126.43 | 274.19 | 301.36 | 754.8 | 400.7 | 777.54 | 139.41 | 657.26 | 245.53 |
| Income Before Tax Ratio
| 0.374 | 0.372 | 0.336 | 0.286 | 0.213 | 0.323 | 0.375 | 0.12 | 0.244 | 0.297 | 0.425 | 0.342 | 0.526 | 0.181 | 0.507 | 0.304 |
| Income Tax Expense
| 159.15 | 151.31 | 162.43 | 103.12 | 58.94 | 141.26 | 150.6 | 31.26 | 105.57 | 48.87 | 292.7 | 4.3 | 195.33 | 62.02 | 169.84 | 88.6 |
| Net Income
| 461.49 | 446.44 | 369.32 | 297.87 | 238.84 | 285.11 | 382.29 | 95.11 | 168.62 | 252.49 | 462.11 | 396.4 | 582.2 | 77.39 | 487.42 | 156.93 |
| Net Income Ratio
| 0.278 | 0.278 | 0.233 | 0.213 | 0.17 | 0.216 | 0.269 | 0.09 | 0.15 | 0.249 | 0.26 | 0.339 | 0.394 | 0.101 | 0.376 | 0.194 |
| EPS
| 5.71 | 5.55 | 4.59 | 3.7 | 2.97 | 3.54 | 4.75 | 1.18 | 2.1 | 3.14 | 5.74 | 4.93 | 22.79 | 3.03 | 19.08 | 6.14 |
| EPS Diluted
| 5.71 | 5.55 | 4.59 | 3.7 | 2.97 | 3.54 | 4.75 | 1.18 | 2.1 | 3.14 | 5.74 | 4.93 | 22.79 | 3.03 | 19.08 | 6.14 |
| EBITDA
| 672.35 | 625.42 | 555.04 | 445.53 | 342.19 | 474.09 | 570.07 | 166.07 | 541.47 | 336.02 | 780.58 | 438.18 | 971.04 | 173.92 | 649.38 | 301.58 |
| EBITDA Ratio
| 0.405 | 0.389 | 0.351 | 0.318 | 0.244 | 0.359 | 0.401 | 0.158 | 0.483 | 0.332 | 0.44 | 0.375 | 0.657 | 0.226 | 0.501 | 0.374 |